drugset / Trial / NCT00532675

Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma.

NCT00532675

Phase 1 Completed 46 enrolled Novartis Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will evaluate the safety of LBH589 given in combination with lenalidomide and dexamethasone in adult patients with multiple myeloma

Timeline

Start
2008-04-22
Primary completion
2017-11-08
Completion
2017-11-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Panobinostat Small molecule 5 mg
Subject Panobinostat Small molecule 10 mg
Subject Panobinostat Small molecule 20 mg
Subject Panobinostat Small molecule 25 mg
Background Lenalidomide Other / unclassified

Indications